SABS
NASDAQSAB Biotherapeutics Inc.
News · 26 weeks45+200%
2026-03-012026-08-23
Mix1690d
- Other8(50%)
- SEC Filings4(25%)
- Earnings2(13%)
- Analyst1(6%)
- Insider1(6%)
Latest news
25 items- SECSEC Form 424B3 filed by SAB Biotherapeutics Inc.424B3 - SAB Biotherapeutics, Inc. (0001833214) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SAB Biotherapeutics Inc.SCHEDULE 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SAB Biotherapeutics Inc.SCHEDULE 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SAB Biotherapeutics Inc.SCHEDULE 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SAB Biotherapeutics Inc.SCHEDULE 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)
- SECSEC Form SCHEDULE 13G filed by SAB Biotherapeutics Inc.SCHEDULE 13G - SAB Biotherapeutics, Inc. (0001833214) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by SAB Biotherapeutics Inc.SCHEDULE 13D/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)
- SECSEC Form 10-Q filed by SAB Biotherapeutics Inc.10-Q - SAB Biotherapeutics, Inc. (0001833214) (Filer)
- PRSAB BIO Reports Q2 2026 Financial Results and Provides Business HighlightsOver 60 clinical sites activated in registrational SAFEGUARD study of SAB-142 in Stage 3 new onset type 1 diabetes; Enrollment remains on track for completion in Q4 2026, with topline data expected in 2H 2027 Breakthrough T1D awarded a grant to PRISE‑hATG study of SAB‑142 in patients with Stage 3 type 1 diabetes who are 100 days to 2 years from diagnosis Operational runway through 2028 to support SAFEGUARD study, PRISE-hATG study and pre-commercial activities Conference call today at 8:30 AM ET MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for ty
- PRSAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ETMIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its second quarter 2026 financial results will be issued on the morning of Thursday, August 6, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates. To access the live conference call, participants may register here. Conference Details: Conference Date: Thursday, August 6, 2026Conference Time: 8:30 AM ETConference Dial-in: 1-800-343-4136International Dial-i
- SECSAB Biotherapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)
- PRBreakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 DiabetesMIAMI, July 07, 2026 (GLOBE NEWSWIRE) -- Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for T1D and other autoimmune diseases, today announced that Breakthrough T1D has awarded a grant to Michael J. Haller, M.D., Professor and Chief of Pediatric Endocrinology at the University of Florida in support of PRISE-hATG, a clinical study evaluating SAB-142 in patients with Stage 3 T1D who are 100 days to 2 years from diagnosis. Stage 3 T1D is diagnosed when the disease has progressed to a point where ins
- INSIDERCHIEF MEDICAL OFFICER Kropotova Alexandra covered exercise/tax liability with 988 shares, decreasing direct ownership by 2% to 42,308 units (SEC Form 4) (withholding tax)4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)
- ANALYSTBarclays initiated coverage on SAB BIO with a new price targetBarclays initiated coverage of SAB BIO with a rating of Overweight and set a new price target of $13.00
- SECSAB Biotherapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)
- PRSAB BIO to Present Data on SAB-142 at The American Diabetes Association's 2026 Scientific Sessions and FOCIS 2026 Annual MeetingMIAMI, May 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that it will present data at two congresses in June. SAB BIO will present an oral presentation at the 2026 Scientific Sessions of the American Diabetes Association® (ADA) being held June 5-8, 2026, in New Orleans, LA. The Company will also present a poster presentation at the Federation of Clinical Immunology Societies (FOCIS) 2026 Annual Meeting being held June 9-12, 2026, in San Francisco, CA. Data to be presented will highlight SAB
- ANALYSTCitigroup initiated coverage on SAB BIO with a new price targetCitigroup initiated coverage of SAB BIO with a rating of Buy and set a new price target of $11.00
- ANALYSTJefferies initiated coverage on SAB BIO with a new price targetJefferies initiated coverage of SAB BIO with a rating of Buy and set a new price target of $11.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by SAB Biotherapeutics Inc.SCHEDULE 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)
- SECSEC Form SCHEDULE 13G filed by SAB Biotherapeutics Inc.SCHEDULE 13G - SAB Biotherapeutics, Inc. (0001833214) (Subject)
- SECSEC Form SCHEDULE 13G filed by SAB Biotherapeutics Inc.SCHEDULE 13G - SAB Biotherapeutics, Inc. (0001833214) (Subject)
- SECSEC Form 10-Q filed by SAB Biotherapeutics Inc.10-Q - SAB Biotherapeutics, Inc. (0001833214) (Filer)
- PRSAB BIO Reports Q1 2026 Financial Results and Recent Business HighlightsContinued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027 Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities Conference call today at 8:30 AM ET MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human an
- PRSAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ETMIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its first quarter 2026 financial results will be issued in the morning of Tuesday, May 12, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates. To access the live conference call, participants may register here. Conference Details: Conference Date: Tuesday, May 12, 2026Conference Time: 8:30 AM ETConference Dial-in: 1-877-704-4453International Dial-in: 1-201
- SECSAB Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - SAB Biotherapeutics, Inc. (0001833214) (Filer)
SABS FAQ
7 questionsWhat does SAB Biotherapeutics Inc. do?
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic for the treatment of COVID-19 advancing as part of the NIH's ACTIV-2 protocol; and SAB-176, a fully-human polyclonal antibody therapeutic candidate designed to bind to type A and B viruses. The company's pre-clinical product...Where does SABS stock trade?
SAB Biotherapeutics Inc. (SABS) is listed on NASDAQ.What sector and industry is SABS in?
SAB Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did SAB Biotherapeutics Inc. go public?
SAB Biotherapeutics Inc. (SABS) completed its IPO in 2021.What are analysts saying about SABS?
SAB Biotherapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $1300.00 price target on 2026-06-24. Recent price targets range from $700.00 to $1500.00.What companies are similar to SABS?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare SABS side-by-side with any of them on Quantisnow.How can I track SABS on Quantisnow?
Quantisnow aggregates SAB Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SABS to receive live email and push alerts on every new disclosure.